A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome
This research study is testing a new medicine called ARO-APOC3 for adults who have a rare inherited condition called Familial Chylomicronemia Syndrome (FCS). People with FCS have very high levels of a certain type of fat in their blood, called triglycerides, which can lead to serious health problems. The main goal of this study is to find out if ARO-APOC3 can safely and effectively reduce these high triglyceride levels. Researchers will compare how much the triglyceride levels change in patients receiving the new medicine versus those receiving a dummy treatment. This is a large-scale study, meaning the results will help confirm if this medicine could be a good new option for people living with FCS.
At a glance
What is this study about?
This study is focusing on Familial Chylomicronemia Syndrome (FCS), which is a very rare and serious genetic condition. If you have FCS, your body has trouble breaking down certain fats from your diet, called triglycerides. This leads to extremely high levels of these fats in your blood. These high levels can cause painful inflammation of the pancreas (a serious condition called pancreatitis), and can also lead to other health problems over time. Because FCS is inherited, it means you're born with it.
Currently, treatment options for FCS are limited and often involve very strict diets. This study aims to see if a new medication, called ARO-APOC3, could offer a new way to help manage FCS. The medicine is designed to target a specific protein in the body that plays a role in how fats are processed. By trying to change how this protein works, researchers hope to significantly lower the high triglyceride levels seen in people with FCS.
The study is in its final stages of testing, called Phase 3. This means it's a large and important step to confirm if the medicine is both effective and safe for widespread use. The results from this study will be crucial in deciding if ARO-APOC3 could become a new approved treatment option for adults living with FCS.
Key takeaways
- Tests a new medicine (ARO-APOC3) for a rare condition called FCS.
- Aims to lower very high fat (triglyceride) levels in the blood.
- Is a major study to confirm if the medicine works and is safe.
- Involves regular clinic visits and medical check-ups over several months.
- Offers potential access to a new treatment, but also carries potential risks.
Who may be eligible?
To join this study, you need to be an adult, at least 18 years old. People of all genders can take part.
The research team will need to check your medical history and do some tests to make sure that taking part in this study is both safe and suitable for you. This will help them confirm that you truly have Familial Chylomicronemia Syndrome (FCS) and meet other specific health requirements for the study.
It's important to remember that not everyone who has FCS will be able to join. There are often other specific health reasons, or certain medications you might be taking, that could mean the study isn't right for you. Your doctor can help you understand if you might be a good fit.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Familial Chylomicronemia Syndrome (FCS)?
- Are you able to attend regular clinic appointments as required by the study?
- Are you willing to potentially receive either the new medicine or a dummy treatment?
- Are you a person of any gender?
What does participation involve?
If you decide to take part, you'll first have a screening visit to check if you're suitable. Once confirmed, you would receive either the new study medication, ARO-APOC3, or a dummy treatment (a 'placebo'). You wouldn't know which one you are getting, and neither would the study team, to make sure the results are fair. Both the active treatment and the placebo would be given as an injection.
Over several months, you would have regular visits to the clinic. These visits would involve check-ups, blood tests to measure your fat levels (like triglycerides and APOC3), and discussions about how you are feeling and any side effects you might experience. These visits are important for the researchers to track how well the medicine is working and to ensure your safety.
The study will follow participants for a period of at least 10 to 12 months. After this time, there might be further follow-up to continue monitoring your health and the long-term effects of the treatment. The total duration of your involvement, including all visits and follow-ups, would be explained in detail before you agree to join.
Potential risks and benefits
Locations (7)
- —UnverifiedIreland
- —UnverifiedFrance
- —UnverifiedSpain
- —UnverifiedBelgium
- —UnverifiedCroatia
- —UnverifiedPoland
- —UnverifiedAustria
Common questions
What is Familial Chylomicronemia Syndrome (FCS)?
FCS is a rare inherited condition where your body can't properly break down certain fats, leading to extremely high fat levels in your blood.
What is ARO-APOC3?
ARO-APOC3 is a new investigational medication being tested to see if it can help lower the high fat levels in the blood of people with FCS.
Why is this study important?
This study is a big step to find out if ARO-APOC3 is a safe and effective new treatment option for people living with FCS, who currently have very limited choices.
Will I definitely get the new medicine?
No, this is a 'blinded' study. You might receive the new medicine or a dummy treatment (placebo), and neither you nor the study team will know which until the study ends.
How long will I be in the study?
Your involvement in the study will last for at least 10 to 12 months, including regular clinic visits and follow-ups.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.